Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposomes × Lymphoid × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡